{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:26:46Z","timestamp":1761823606842},"reference-count":34,"publisher":"Elsevier BV","issue":"4","content-domain":{"domain":["geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.jgo.2013.05.007","type":"journal-article","created":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T15:05:33Z","timestamp":1374073533000},"page":"362-367","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["HER2 status in elderly women with breast cancer"],"prefix":"10.1016","volume":"4","author":[{"given":"Heather S.","family":"Laird-Fick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph C.","family":"Gardiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemasri","family":"Tokala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyank","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sainan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolay V.","family":"Dimitrov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jgo.2013.05.007_bb0005","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.1365-2559.2003.01542.x","article-title":"Breast carcinoma in women over the age of 85: distinct histological pattern and androgen, oestrogen, and progesterone receptor status","volume":"42","author":"Honma","year":"2003","journal-title":"Histopathology"},{"key":"10.1016\/j.jgo.2013.05.007_bb0010","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/1097-0142(20000901)89:5<1121::AID-CNCR22>3.0.CO;2-G","article-title":"Breast cancer in the very elderly Dutch population","volume":"89","author":"deRijke","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.jgo.2013.05.007_bb0015","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1634\/theoncologist.2010-0234","article-title":"Lack of survival gain for elderly women with breast cancer","volume":"16","author":"Bastiaannet","year":"2011","journal-title":"Oncologist"},{"issue":"27","key":"10.1016\/j.jgo.2013.05.007_bb0020","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJM199912303412706","article-title":"Underrepresentation of patients 65years of age or older in cancer-treatment trials","volume":"341","author":"Hutchins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2013.05.007_bb0025","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1634\/theoncologist.2011-0384","article-title":"A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316)","volume":"17","author":"Javid","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.jgo.2013.05.007_bb0030","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials: race-, sex-, and age-based disparities","volume":"291","author":"Murthy","year":"2004","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.jgo.2013.05.007_bb0035","doi-asserted-by":"crossref","first-page":"S250","DOI":"10.1111\/j.1532-5415.2009.02504.x","article-title":"Clinical management update: evaluation and management of older patients with breast cancer","volume":"57","author":"Owusu","year":"2009","journal-title":"J Am Geriatr Soc"},{"issue":"12","key":"10.1016\/j.jgo.2013.05.007_bb0040","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1245\/s10434-007-9500-y","volume":"14","author":"Stewart","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jgo.2013.05.007_bb0045","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1200\/JCO.2007.14.2364","article-title":"American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer","volume":"25","author":"Harris","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2013.05.007_bb0190","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1200\/JCO.2007.14.8197","article-title":"Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations","volume":"27","author":"Sauter","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2013.05.007_bb0060","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/annonc\/mdq593","article-title":"The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis","volume":"22","author":"Harris","year":"2011","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2013.05.007_bb0065","doi-asserted-by":"crossref","first-page":"e21030","DOI":"10.1371\/journal.pone.0021030","article-title":"Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials","volume":"6","author":"Yin","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jgo.2013.05.007_bb0070","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"issue":"34","key":"10.1016\/j.jgo.2013.05.007_bb0075","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1200\/JCO.2011.36.7045","article-title":"Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer","volume":"29","author":"Perez","year":"2011","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.jgo.2013.05.007_bb0080","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1200\/JCO.2011.35.6725","article-title":"Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study","volume":"30","author":"Blackwell","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jgo.2013.05.007_bb0085","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S1470-2045(12)70329-7","article-title":"Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I\u2013III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial","volume":"13","author":"Ismael","year":"2012","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2013.05.007_bb0090","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10549-010-0838-7","article-title":"Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group Trial E3198","volume":"121","author":"Wolff","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"10.1016\/j.jgo.2013.05.007_bb0095","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1503\/cmaj.061011","article-title":"Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis","volume":"176","author":"Dendukuri","year":"2007","journal-title":"CMAJ"},{"key":"10.1016\/j.jgo.2013.05.007_bb0100","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"131","author":"Wolff","year":"2007","journal-title":"Arch Pathol Lab Med"},{"issue":"7","key":"10.1016\/j.jgo.2013.05.007_bb0105","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1136\/jcp.2006.040840","article-title":"External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme","volume":"60","author":"Bartlett","year":"2007","journal-title":"J Clin Pathol"},{"issue":"11","key":"10.1016\/j.jgo.2013.05.007_bb0110","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/jnci\/94.11.852","article-title":"Real-world performance of HER2 testing \u2014 national surgical adjuvant breast and bowel project experience","volume":"94","author":"Paik","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jgo.2013.05.007_bb0115","doi-asserted-by":"crossref","first-page":"6598","DOI":"10.1158\/1078-0432.CCR-05-0636","article-title":"Diagnostic evaluation of HER-2 as a Molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials","volume":"11","author":"Press","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jgo.2013.05.007_bb0120","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.2005.03.4744","article-title":"HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial","volume":"24","author":"Perez","year":"2006","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.jgo.2013.05.007_bb0195","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.2002.09.094","article-title":"Evaluation of HER-2\/neu Gene Amplification and Overexpression: Comparison of Frequently Used Assay Methods in a Molecularly Characterized Cohort of Breast Cancer Specimens","volume":"20","author":"Press","year":"2002","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jgo.2013.05.007_bb0135","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/jnci\/92.7.550","article-title":"Tumor characteristics and clinical outcome of elderly women with breast cancer","volume":"92","author":"Diab","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.jgo.2013.05.007_bb0140","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1040-8428(02)00144-0","article-title":"Primary breast cancer in elderly women: biological profile and relation with clinical outcome","volume":"45","author":"Daidone","year":"2003","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"10.1016\/j.jgo.2013.05.007_bb0145","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/cncr.20535","article-title":"Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopausal patients","volume":"101","author":"Gennari","year":"2004","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.jgo.2013.05.007_bb0150","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.critrevonc.2006.01.007","article-title":"Pathological, biological and clinical characteristics, and surgical management, of elderly women with breast cancer","volume":"59","author":"Molino","year":"2006","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"10.1016\/j.jgo.2013.05.007_bb0155","first-page":"422","article-title":"Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer","volume":"37","author":"van de Ven","year":"2011","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"10.1016\/j.jgo.2013.05.007_bb0160","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/jcp.49.11.920","article-title":"Prognostic role of oestrogen and progesterone receptors in patients with breast cancer: relation to age and lymph node status","volume":"49","author":"Collett","year":"1996","journal-title":"J Clin Pathol"},{"issue":"4","key":"10.1016\/j.jgo.2013.05.007_bb0165","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/(SICI)1097-0142(19980815)83:4<698::AID-CNCR10>3.0.CO;2-N","article-title":"Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause","volume":"83","author":"Pujol","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.jgo.2013.05.007_bb0170","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/archinte.1996.00440010103014","article-title":"The effect of age and comorbidity in the treatment of elderly women with nonmetastatic breast cancer","volume":"156","author":"Newschaffer","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jgo.2013.05.007_bb0175","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/modpathol.2009.82","article-title":"Comparison of fluorescent in situ hybridization HER-2\/neu results on core needle biopsy and excisional biopsy in primary breast cancer","volume":"22","author":"Apple","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jgo.2013.05.007_bb0185","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/annonc\/mdp234","article-title":"Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC)","volume":"20","author":"Arnedos","year":"2009","journal-title":"Ann Oncol"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406813000714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406813000714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T13:47:46Z","timestamp":1646142466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406813000714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S1879406813000714"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2013.05.007","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HER2 status in elderly women with breast cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2013.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}